BioAdaptives, Inc. develops and markets nutraceutical and wellness products for cognitive performance, brain recovery, pet vitality and weight management. Company news centers on the MyndSystem platform, including MyndMed for daytime cognitive support and MyndRenew for nighttime recovery support, as well as NeuroRush, PawPa Regen dog chews and Zeranovia.
Recurring updates cover product launches, direct-to-consumer availability, formulation positioning, pilot and dosage testing, athlete-safety testing for MyndMed, and expansion of pet-wellness and nootropic product lines.
BioAdaptives (OTC: BDPT) detailed the scientific strategy for its Xcellara™ cellular wellness platform ahead of the planned August 1, 2026 launch of XcellaraHeart™. The platform is built on two pillars: stem cell “Supply” via a clinically studied mobilization base and “Direction” through tissue‑specific signaling support.
The Xcellara™ base was evaluated in a human randomized controlled trial, reporting an average 268.8% increase in circulating stem/progenitor‑type cells. Direction is pursued by pairing this base with ingredients that support natural signaling pathways such as the SDF‑1α/CXCR4 axis. XcellaraHeart™ combines the base with Tanshinone IIA, a Danshen‑derived compound studied in cardiovascular research for its effects on this pathway. BioAdaptives plans additional Xcellara™ derivatives across wellness areas including joint, skin, nerve, cognitive and metabolic support, introduced on a regular cadence.
BioAdaptives (OTC: BDPT) announced upcoming commercial availability of XcellaraHeart™, a cardiovascular wellness supplement combining the Xcellara™ stem/progenitor cell mobilization base with Tanshinone IIA, a Danshen-derived compound. The Xcellara™ base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks.
According to BioAdaptives, XcellaraHeart™ targets two areas: stem/progenitor cell “supply” and cardiovascular repair-related signaling support via pathways studied around the SDF-1α/CXCR4 chemokine axis. A scientific evidence dossier and ordering will be available online, with orders opening August 1, 2026 and first deliveries expected in early August.
BioAdaptives (OTC:BDPT) announced TruShield certification for its nighttime formula MyndRenew, confirming compliance with WADA and UFC anti-doping standards. Together with previously certified MyndMed, the full MyndSystem platform is now a 24/7, independently verified cognitive performance and repair system for professional athletes.
The company highlights potential access to elite sports markets, broader consumer trust across fighters, executives, and active seniors, and expanded commercialization opportunities. MyndSystem products are available online, with a 30-day system priced at $159.90 (or $119.93 by subscription) and a 14-day pack at $59.95.
BioAdaptives (OTC: BDPT) launched MyndSystem™, a stimulant-free, dual-phase cognitive support platform combining daytime and nighttime formulas for a 24-hour brain support cycle.
MyndMed™ targets daytime performance, while MyndRenew™ focuses on overnight repair. A 30-day system costs $159.90 one-time or $119.93 by subscription at myndsystem.com.
BioAdaptives (OTC: BDPT) launched MyndRenew on May 6, 2026, a nighttime dietary supplement aimed at supporting sleep quality and the brain's overnight recovery processes as part of the MyndSystem platform.
MyndRenew contains 13 ingredients at research-consistent levels, including magnesium glycinate, apigenin, PEA, and lion's mane extract, and is available now at www.myndsystem.com.
BioAdaptives (OTC: BDPT) launched MyndSystem™, a two-product neuro-performance and repair system for day and night, on April 28, 2026. MyndMed™ (day) targets focus, clarity, endurance, and stress resilience; MyndRenew™ (night) targets Delta-wave sleep, glymphatic waste removal, and mitochondrial repair. The company published a clinical evidence library and launched a direct-to-consumer website at www.MyndSystem.com. BioAdaptives will share updates via X at @BioAdaptivesInc.
BioAdaptives (OTC: BDPT) announced the commercial launch of MyndMed™, a cognitive-support dietary supplement available online as of October 7, 2025.
The company said MyndMed™ combines well-studied nutrients targeting cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity, and that manufacturing occurs in cGMP-certified U.S. facilities with third‑party testing and transparent labeling. BioAdaptives is scaling production to meet expected high order volumes beginning in November and offers nationwide U.S. shipping, introductory promotions, and subscription options at www.MyndMed.com.
BioAdaptives (OTCMKTS: BDPTD) announced that its nootropic supplement MyndMed™ has received full clearance from TruShield™ Laboratory Services, confirming compliance with World Anti-Doping Agency (WADA) and Ultimate Fighting Championship (UFC) standards.
The comprehensive testing verified that MyndMed™, which combines botanical extracts, amino acids, and neuro-support nutrients, contains no banned or prohibited substances. This certification enables UFC athletes to use the supplement without concerns about anti-doping violations.
The product is designed to enhance focus, reaction time, and cognitive performance while supporting neurotransmitter balance and neural resilience for athletes under high-stress competition conditions.
BioAdaptives (OTC:BDPTD) announced the national launch of NeuroRush™, a next-generation nootropic supplement, scheduled for commercial release in August/September 2025. The product combines six clinically studied ingredients including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens.
The supplement will be available in two formulations: one with natural caffeine and a caffeine-free version. Following successful test market results, the company plans to distribute NeuroRush™ through online retailers, direct-to-consumer channels, and health & wellness partners nationwide.
BioAdaptives (OTC Pink: BDPTD) announced the nationwide launch of Pawpa™ Regen, a revolutionary canine supplement designed to promote regenerative healing through stem cell activation in aging dogs. Following a successful limited market release, the product will be available nationwide through e-commerce platforms by late July 2025.
The proprietary formula works by stimulating the release of circulating stem cells, leading to improvements in vitality, mobility, and overall wellness in older dogs. Early testing has shown positive results in energy levels, coat health, mobility, and temperament. The company is scaling production to meet anticipated strong demand in the pet wellness market.